Plus Therapeutics Provides Updates on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire) - Nov 19, 2022 - P1/2a | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "The Company's second oral presentation...highlighted data from the first two cohorts which demonstrates the potential of rhenium (186Re) obisbemeda to treat LM: As single rhenium (186Re) obisbemeda dose administered through an intraventricular catheter (Ommaya reservoir) at 6.6 mCi in 5.0 mL in Cohort 1 achieved absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid space, which was well tolerated with no treatment-related adverse events of greater than grade 1; All four patients treated to date in Cohorts 1 and 2 were observed to have prompt and complete rhenium (186Re) obisbemeda distribution throughout the cerebrospinal fluid (CSF) subarachnoid space that was durable to 28 days."
P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|